Samuel Chen's firm, which controls Taiwan's Polaris Group, is the second-largest shareholder of Regencell Bioscience, while the SEC considers new rules for foreign issuers.
1 report, 0 independent
Updated Jun 28
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Samuel Chen's firm, which controls Taiwan's Polaris Group, is the second-largest shareholder of Regencell Bioscience, while the SEC considers new rules for foreign issuers.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Samuel Chen
researcher
Nothing else this week.
-
Regencell Bioscience
traditional Chinese herbal treatment company
Nothing else this week.
-
SEC
Slovak company
Coverage
Newest first; wire copies grouped- Unknown outlet